Overall, the growing understanding of metabolic rewiring and the identification of distinct metabolic vulnerabilities in FLT3-mutated AML have opened new avenues for novel therapeutic approaches, supporting the rationale for combining FLT3 inhibitors with agents targeting mitochondrial metabolism, glycolysis, glutaminolysis, and lipid pathways. This evidence concerns the gene FLT3 and acute myeloid leukemia.